Is CONVULSION a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed CONVULSION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 63 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported CONVULSION to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and CONVULSION. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause CONVULSION, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes CONVULSION. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if CONVULSION ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing CONVULSION: 63
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where CONVULSION is a reported side effect: 1.8925%

FDA reports of any drug causing CONVULSION : 64904
Average percentage for all medicated patients where CONVULSION is reported as a complication: 0.4068%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with CONVULSION:

SEROQUEL (4060 patients)
KEPPRA (3407 patients)
DILANTIN (3088 patients)
VIOXX (3003 patients)
AVONEX (2696 patients)
ASPIRIN (2681 patients)
LAMICTAL (2451 patients)
TEGRETOL (2091 patients)
NEURONTIN (1865 patients)
TYSABRI (1804 patients)
TOPAMAX (1640 patients)
LYRICA (1638 patients)
LAMOTRIGINE (1551 patients)
DEPAKOTE (1526 patients)
XANAX (1387 patients)
REBIF (1339 patients)
TRILEPTAL (1319 patients)
ZOLOFT (1317 patients)
PAXIL (1297 patients)
PHENYTOIN (1297 patients)
WELLBUTRIN (1291 patients)
LEXAPRO (1276 patients)
LIPITOR (1265 patients)
CLONAZEPAM (1236 patients)
CYMBALTA (1223 patients)
OMEPRAZOLE (1219 patients)
FOSAMAX (1205 patients)
CARBAMAZEPINE (1182 patients)
LEVETIRACETAM (1168 patients)
PREDNISONE (1167 patients)
CHANTIX (1140 patients)
VALPROATE SODIUM (1136 patients)
ACETAMINOPHEN (1114 patients)
SYNTHROID (1111 patients)
NEXIUM (1096 patients)
FOLIC ACID (1062 patients)
ZYPREXA (1042 patients)
METHOTREXATE (1029 patients)
LASIX (1028 patients)
LORAZEPAM (997 patients)
LISINOPRIL (984 patients)
KLONOPIN (969 patients)
RISPERDAL (967 patients)
CLOZARIL (966 patients)
HEPARIN SODIUM INJECTION (933 patients)
GABAPENTIN (930 patients)
ATIVAN (916 patients)
DEPAKENE (873 patients)
ATENOLOL (865 patients)
TOPIRAMATE (857 patients)
AMBIEN (847 patients)
DIAZEPAM (829 patients)
BACLOFEN (817 patients)
IBUPROFEN (801 patients)
TRAMADOL HCL (795 patients)
SIMVASTATIN (794 patients)
LEVOTHYROXINE SODIUM (785 patients)
FUROSEMIDE (781 patients)
SUBOXONE (775 patients)
ALBUTEROL (748 patients)
PROZAC (746 patients)
PLAVIX (743 patients)
EFFEXOR (742 patients)
REMICADE (737 patients)
PREDNISOLONE (733 patients)
PHENOBARBITAL TAB (730 patients)
DEXAMETHASONE (715 patients)
NORVASC (709 patients)
HUMIRA (698 patients)
COUMADIN (692 patients)
LANTUS (688 patients)
VICODIN (683 patients)
ABILIFY (658 patients)
PROTONIX (652 patients)
HYDROCHLOROTHIAZIDE (649 patients)
VALPROIC ACID (645 patients)
PREVACID (636 patients)
ZOCOR (636 patients)
OXYCONTIN (634 patients)
PRILOSEC (620 patients)
BETASERON (608 patients)
FORTEO (600 patients)
DURAGESIC-100 (592 patients)
SINGULAIR (591 patients)
CITALOPRAM HYDROBROMIDE (585 patients)
EFFEXOR XR (584 patients)
TRAZODONE HCL (584 patients)
TOPROL-XL (582 patients)
POTASSIUM CHLORIDE (576 patients)
DECADRON (571 patients)
VALIUM (566 patients)
VITAMIN D (564 patients)
CELEBREX (563 patients)
DIGOXIN (554 patients)
INSULIN (547 patients)
ULTRAM (528 patients)
CYCLOPHOSPHAMIDE (522 patients)
CLOZAPINE (516 patients)
ZOFRAN (513 patients)
CYCLOSPORINE (513 patients)
MORPHINE (513 patients)
VIMPAT (512 patients)
PREDNISONE TAB (506 patients)
ENBREL (505 patients)
PROGRAF (500 patients)
ZOMETA (499 patients)
ALPRAZOLAM (486 patients)
CELEXA (483 patients)
PERCOCET (483 patients)
FENTANYL (478 patients)
MIRTAZAPINE (477 patients)
OXCARBAZEPINE (476 patients)
DIOVAN (474 patients)
ARICEPT (463 patients)
WARFARIN SODIUM (462 patients)
METFORMIN HCL (452 patients)
LEVAQUIN (450 patients)
AMITRIPTYLINE HCL (449 patients)
ZYRTEC (446 patients)
AMPYRA (445 patients)
BENADRYL (431 patients)
HALDOL (430 patients)
DIANEAL (428 patients)
METOPROLOL TARTRATE (418 patients)
AMLODIPINE (417 patients)
ZANTAC (416 patients)
TYLENOL (CAPLET) (411 patients)
YASMIN (409 patients)
CALCIUM (406 patients)
CLONIDINE (404 patients)
LORTAB (403 patients)
HUMALOG (403 patients)
LIORESAL (403 patients)
CRESTOR (402 patients)
ALLOPURINOL (402 patients)
WELLBUTRIN XL (401 patients)
AVASTIN (401 patients)
STRATTERA (400 patients)
MULTI-VITAMINS (396 patients)
MULTI-VITAMIN (392 patients)
LOVENOX (390 patients)
GEODON (385 patients)
ACCUTANE (385 patients)
GABITRIL (384 patients)
LANSOPRAZOLE (382 patients)
PAROXETINE HCL (381 patients)
PROVIGIL (375 patients)
LACOSAMIDE (372 patients)
SEROQUEL XR (370 patients)
ADVAIR DISKUS 100/50 (369 patients)
YAZ (364 patients)
NITROGLYCERIN (362 patients)
OXYCODONE HCL (360 patients)
RIBAVIRIN (360 patients)
DILANTIN-125 (360 patients)
TYLENOL (360 patients)
PHENYTOIN SODIUM (360 patients)
PEGASYS (359 patients)
AMOXICILLIN (356 patients)
CISPLATIN (355 patients)
FLUOXETINE (354 patients)
CYTARABINE (353 patients)
RISPERIDONE (353 patients)
ACYCLOVIR (352 patients)
RANITIDINE (349 patients)
REGLAN (348 patients)
BACTRIM (345 patients)
METHYLPREDNISOLONE (344 patients)
PRIMAXIN (344 patients)
TAMIFLU (342 patients)
ZONISAMIDE (339 patients)
REVLIMID (337 patients)
COPAXONE (336 patients)
CIPROFLOXACIN (331 patients)
PREMARIN (330 patients)
NAMENDA (325 patients)
ZONEGRAN (325 patients)
FAMOTIDINE (323 patients)
RAMIPRIL (323 patients)
ALL OTHER THERAPEUTIC PRODUCTS (321 patients)
NEORAL (320 patients)
FLEXERIL (319 patients)
METHADONE HCL (319 patients)
SOLU-MEDROL (314 patients)
ALLEGRA (312 patients)
AVELOX (311 patients)
PROPRANOLOL (310 patients)
VANCOMYCIN (310 patients)
GILENYA (308 patients)
FLUOROURACIL (306 patients)
PANTOPRAZOLE (306 patients)
METOCLOPRAMIDE (302 patients)
MORPHINE SULFATE (302 patients)
GLUCOPHAGE (300 patients)
ASCORBIC ACID (297 patients)
DEPAKOTE ER (295 patients)
LITHIUM CARBONATE (294 patients)
AVANDIA (291 patients)
REMERON (286 patients)
LIDOCAINE (286 patients)
AREDIA (284 patients)
ZITHROMAX (284 patients)
VINCRISTINE (283 patients)
ETOPOSIDE (283 patients)
FLUCONAZOLE (282 patients)
VITAMIN E (280 patients)
METOPROLOL (280 patients)
CALCIUM CARBONATE (279 patients)
PEPCID (278 patients)
BEVACIZUMAB (276 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about CONVULSION and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.